Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials.
暂无分享,去创建一个
M. S. Merrill | E. Winer | E. Cerami | L. Trippa | L. Macconaill | R. Bose | N. Lin | D. Dillon | N. Lindeman | M. Hughes | N. Wagle | R. Barroso-Sousa | S. Tolaney | P. Kumari | I. Krop | R. Freedman | Cynthia X. Ma | M. Lloyd | Rebecca A. Santiago | A. Garrido-Castro | Lindsey Crowley | P. Exman | S. Di Lascio | C. Ma | B. Johnson | B. Bychkovsky | Tianyu Li | Colin Mackichan | M. Krevalin | N. Kuhnly | J. Files | M. Merrill | Brittany L Bychkovsky | Janet L. Files | Brittany L. Bychkovsky | N. Kuhnly
[1] U. Matulonis,et al. The NCI-MATCH trial and precision medicine in gynecologic cancers. , 2018, Gynecologic oncology.
[2] James Lindsay,et al. MatchMiner: An open source computational platform for real-time matching of cancer patients to precision medicine clinical trials using genomic and clinical criteria , 2017, bioRxiv.
[3] M. Ellis,et al. Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer , 2017, Clinical Cancer Research.
[4] Mariella G. Filbin,et al. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors , 2017, Neuro-oncology.
[5] Tianfeng Wang,et al. HER2 somatic mutations are associated with poor survival in HER2‐negative breast cancers , 2017, Cancer science.
[6] L. Macconaill,et al. Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. , 2017, Archives of pathology & laboratory medicine.
[7] Marian Harris,et al. Institutional implementation of clinical tumor profiling on an unselected cancer population. , 2016, JCI insight.
[8] P. Campbell,et al. Genomic Characterization of Primary Invasive Lobular Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] R. Yelensky,et al. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. , 2016, Cancer research.
[10] J Jack Lee,et al. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Funda Meric-Bernstam,et al. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] E. Mardis,et al. Prioritizing targets for precision cancer medicine. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] Thomas Bachelot,et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). , 2014, The Lancet. Oncology.
[14] John M S Bartlett,et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.
[15] John M S Bartlett,et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Li Ding,et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.
[17] Keith L. Ligon,et al. Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples , 2009, PloS one.